Cover Image
市場調查報告書

腎上腺皮質癌症:開發中產品分析

Adrenocortical Carcinoma - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 213047
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
腎上腺皮質癌症:開發中產品分析 Adrenocortical Carcinoma - Pipeline Review, H1 2017
出版日期: 2017年05月16日 內容資訊: 英文 63 Pages
簡介

腎上腺皮質癌是腎上腺皮質腫瘤增生的罕見疾病。發病因子有姓別、影響腎上腺的遺傳疾病、高齡、吸煙等,症狀有高血糖、高血壓、下肢肌肉無力、胸部及腹部過度脂肪堆積、臉部及體毛增加、聲音變低等。

本報告提供全球各國治療腎上腺皮質癌症所用的開發中產品之開發情形相關分析,提供開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

腎上腺皮質癌症概要

治療藥的開發

  • 腎上腺皮質癌症開發中產品:概要
  • 各企業的治療藥
  • 企業開發中的產品

腎上腺皮質癌症:治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 分子各類型

腎上腺皮質癌症開發治療藥的企業

  • ArQule Inc
  • EnGeneIC Ltd
  • Exelixis Inc
  • Merck KGaA
  • Millendo Therapeutics Inc
  • Orphagen Pharmaceuticals Inc

腎上腺皮質癌症:治療藥簡介

腎上腺皮質癌症治療藥:開發暫停中的計劃

腎上腺皮質癌症治療藥:開發中止的產品

腎上腺皮質癌症相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9278IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenocortical Carcinoma - Pipeline Review, H1 2017, provides an overview of the Adrenocortical Carcinoma (Oncology) pipeline landscape.

Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. Predisposing factors include female, hereditary disease that affects the adrenal glands, age and smoking. Symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in chest and abdomen, early signs of puberty in children, increased facial and body hair, particularly in females and deepened voice in females.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenocortical Carcinoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adrenocortical Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Discovery stages are 6 and 1 respectively.

Adrenocortical Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Adrenocortical Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Adrenocortical Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Adrenocortical Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Adrenocortical Carcinoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Adrenocortical Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview
    • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development
    • ArQule Inc
    • EnGeneIC Ltd
    • Exelixis Inc
    • Merck KGaA
    • Millendo Therapeutics Inc
    • Orphagen Pharmaceuticals Inc
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Drug Profiles
    • ARQ-087 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATR-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avelumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cabozantinib s-malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize SF-1 for Cushingis Syndrome, Endometriosis and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TargomiRs - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones
    • Featured News & Press Releases
      • Mar 28, 2017: Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing's Syndrome
      • Mar 18, 2016: Millendo Therapeutics Announces Publication of Preclinical Data for ATR-101 and Data Presentations at ENDO 2016
      • Mar 03, 2015: Atterocor Announces Data Presentations at ENDO 2015
      • Dec 11, 2014: Atterocor Expands Phase 1 Trial of ATR-101 to Additional Leading Adrenal Cancer Centers
      • Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by ArQule Inc, H1 2017
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by EnGeneIC Ltd, H1 2017
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Exelixis Inc, H1 2017
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck KGaA, H1 2017
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Millendo Therapeutics Inc, H1 2017
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals Inc, H1 2017
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, H1 2017
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top